Sermorelin Frequently Asked Questions

Sermorelin (also known as GRF 1-29 NH2) is a synthetic 29-amino acid peptide representing the shortest fully functional fragment of growth hormone-releasing hormone (GHRH). It retains full biological activity for stimulating GH release from the pituitary gland. Peptides Pharma Sermorelin is formulated at >99% purity in a lyophilized vial.

Sermorelin binds to the GHRH receptor on anterior pituitary somatotroph cells, stimulating the synthesis and secretion of endogenous growth hormone in a pulsatile, physiological pattern. Unlike exogenous GH administration, Sermorelin works through the body's own regulatory feedback mechanisms, which may help preserve normal GH axis function. These observations are from published clinical and preclinical research.

Sermorelin is studied in research related to growth hormone deficiency, age-related GH decline, body composition, sleep quality, bone density, and pituitary function testing. Its physiological mechanism of GH stimulation makes it particularly valuable for studies requiring preserved feedback regulation.

Peptides Pharma Sermorelin is manufactured to >99% purity in GMP-certified, ISO 7 cleanroom facilities. Each batch undergoes independent HPLC and mass spectrometry testing. Certificates of Analysis confirming identity, purity, and sterility are available for all batches.

Lyophilized Sermorelin should be stored at -20°C for long-term storage or 2-8°C for short-term use. Protect from light and moisture. Once reconstituted, store at 2-8°C and use within 28 days for optimal peptide stability.

Reconstitute Sermorelin by adding bacteriostatic water slowly down the inner wall of the vial. Allow the lyophilized powder to dissolve gently without agitation — swirl carefully if needed. The reconstitution volume should be selected to achieve the target concentration for your research protocol.

Reconstituted Sermorelin stored at 2-8°C with bacteriostatic water is generally stable for up to 28 days. Maintain aseptic technique when drawing from the vial to prevent contamination and preserve peptide quality.

Yes. Peptides Pharma Sermorelin is supplied exclusively for laboratory and research use. While Sermorelin has been used clinically under certain brand names, Peptides Pharma's formulation is sold strictly as a research compound and is not intended for therapeutic application.

Both Sermorelin and CJC-1295 are GHRH analogues that stimulate the GHRH receptor, but they differ in half-life and duration of action. Sermorelin has a shorter half-life (approximately 10-20 minutes) producing more natural, pulsatile GH release, while CJC-1295 has structural modifications that extend its half-life significantly. The choice between them depends on the research protocol requirements.

Sermorelin is commonly studied in combination with GH secretagogues such as Ipamorelin or GHRP-6 for synergistic GH stimulation through complementary receptor pathways. Sermorelin acts on the GHRH receptor while secretagogues act on the ghrelin receptor, potentially amplifying growth hormone release. Protocol design should follow published literature.